HLX13
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for HLX13, covering 2025-02-24 to 2026-03-16. Get the full timeline:
Most recent: Clinical Trial Update: Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma [Phase 1]